About Histone deacetylase 3
Histone deacetylase 3 (HDAC3) is a protein
from Homo sapiens identified by UniProt accession
O15379, 428 residues long.
MolForge cross-references it against 0 known binders and
528 disease associations.
Target properties
| Protein name | Histone deacetylase 3 |
| UniProt accession | O15379 |
| Gene | HDAC3 |
| Organism | Homo sapiens |
| Length | 428 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (8)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (528)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.57
- multiple myeloma · score 0.57
- neurodegenerative disease · score 0.53
- unspecified peripheral T-cell lymphoma · score 0.52
- Cutaneous T-cell lymphoma · score 0.51
- T-cell non-Hodgkin lymphoma · score 0.50
- graft versus host disease · score 0.39
- primary myelofibrosis · score 0.38
- viral disease · score 0.38
- lymphoma · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15379-F1 | alphafold | PREDICTED | 90.78 | — |
Amino-acid sequence (428 residues)
MAKTVAYFYD PDVGNFHYGA GHPMKPHRLA LTHSLVLHYG LYKKMIVFKP YQASQHDMCR FHSEDYIDFL QRVSPTNMQG FTKSLNAFNV GDDCPVFPGL FEFCSRYTGA SLQGATQLNN KICDIAINWA GGLHHAKKFE ASGFCYVNDI VIGILELLKY HPRVLYIDID IHHGDGVQEA FYLTDRVMTV SFHKYGNYFF PGTGDMYEVG AESGRYYCLN VPLRDGIDDQ SYKHLFQPVI NQVVDFYQPT CIVLQCGADS LGCDRLGCFN LSIRGHGECV EYVKSFNIPL LVLGGGGYTV RNVARCWTYE TSLLVEEAIS EELPYSEYFE YFAPDFTLHP DVSTRIENQN SRQYLDQIRQ TIFENLKMLN HAPSVQIHDV PADLLTYDRT DEADAEERGP EENYSRPEAP NEFYDGDHDN DKESDVEI
Explore Histone deacetylase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets